Loading…
Custom synthesis and manufacturing (CDMO) of specialty chemicals mainly for global agrochemical and pharmaceutical companies.
Custom synthesis and manufacturing (CDMO) of specialty chemicals mainly for global agrochemical and pharmaceutical companies.
Makes intermediates to a customer's own molecule under long-term contracts, often exclusive, so the buyer supplies the design and Anupam the chemistry and plant capacity. A small number of global agrochemical companies account for much of sales.
In one line: A specialty-chemical custom manufacturer for agrochem/pharma.
Moat: narrow (process know-how, customer qualification). Long-term supply contracts tied to a customer's registered molecule create switching costs.
Headquarters: Surat, India · Founded: 1984 · Employees: 2,931
Size Anupam Rasayan India (ANURAS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.40B, the 488th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,165 on 6 Nov 2026.
Performance Over six months the shares fell 14.8%, against -17.1% for the median peer and 0.0% for the India market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 51.8% over the last twelve months (peer median +17.1%); the operating margin is 15.7% (peer median 3.7%).
Valuation It trades at 45.8× forward earnings against a peer median of 15.2× (4th most expensive of 11).
Capital Return on invested capital runs 8.1 points below its cost of capital (14.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹25.3B | ₹23.6B | ₹14.3B | ₹14.7B | ₹15.9B |
| Revenue growth | — | +65% | -2% | -8% | — |
| Gross profit | ₹8.74B | ₹5.31B | ₹4.05B | ₹4.02B | ₹4.51B |
| EBITDA | ₹5.63B | ₹5.40B | ₹4.03B | ₹3.81B | ₹4.28B |
| Net income | ₹1.75B | ₹1.70B | ₹933M | ₹1.29B | ₹1.81B |
| Free cash flow | n/a | -₹3.57B | -₹5.45B | -₹7.39B | ₹141M |
| Capital expenditure | n/a | ₹5.55B | ₹4.10B | ₹7.16B | ₹2.21B |
| Total debt | n/a | ₹18.7B | ₹14.3B | ₹10.7B | ₹8.22B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Anupam Rasayan India ANURAS.NS | $1.40B | -15% | +52% | 16% | 45.8× | n/a |
| PI Industries PIIND.NS | $2.79B | -44% | -15% | 13% | 22.7× | n/a |
| Srf SRF.NS | $7.67B | -11% | +20% | 19% | 30.3× | 25.2% |
| Navin Fluorine International NAVINFLUOR.NS | $4.89B | +27% | +46% | 30% | 45.6× | 34.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ANURAS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | 0.0% | -6.6% | 8th highest of 21 |
| 6-month return | -14.8% | -17.1% | 10th highest of 21 |
| Distance from 52-week high | -17.6% | -42.2% | 5th highest of 21 |
| Revenue growth (TTM) | +51.8% | +17.1% | 4th highest of 18 |
| Operating margin | 15.7% | 3.7% | 5th highest of 18 |
| Forward P/E | 45.8× | 15.2× | 4th most expensive of 11 |
| ROIC minus cost of capital | -8.1 pp | -4.1 pp | 7th lowest of 17 |
| EV / EBITDA | 23.5× | 9.4× | most expensive of 7 |
| Net debt / EBITDA | 2.6× | 0.3× | 3rd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 45.8× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 71.6× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 585.0× | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | n/a | n/a | n/a |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 9.4× | -15.4% | +3.9% |
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 7.7× | -17.5% | +7.0% |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.37B | -32% | +21% | -127% | n/a | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | n/a | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 11.8× | 14.9% | +11.1% |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 24.2× | 31.6% | +16.6% |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 50.3× | 26.1% | +23.1% |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 9.1× | -7.4% | +12.7% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 18.6× | 0.3% | -1.3% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 8.4× | -2.4% | +13.8% |